Oculis Holding AG to Engage Investors at September Events

Oculis Holdings Engaging in Key Investor Conferences This September

Oculis Holding AG (Nasdaq: OCS / Iceland: OCS), a leading biopharmaceutical company from Switzerland focusing on innovative solutions for ophthalmic and neuro-ophthalmic diseases, is gearing up for a month of critical investor outreach. Their management team will participate in several investor conferences throughout September, providing an excellent opportunity for investors to engage with the company directly and learn more about their groundbreaking work.

Upcoming Conference Schedule

Wells Fargo Healthcare Conference

The first major event on Oculis's agenda is the Wells Fargo Healthcare Conference, taking place from September 3-5 in Boston. Riad Sherif, M.D., the Chief Executive Officer, along with Chief Financial Officer Sylvia Cheung will represent the company. With insightful discussions planned, this conference is anticipated to lay the groundwork for future collaborations and insights into the biopharmaceutical landscape.

H.C. Wainwright 27th Annual Global Investment Conference

Following that, Oculis will take part in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10 in New York. A highlight of this conference will be a fireside chat with Dr. Sherif, scheduled for September 8 at 2:30 PM ET. This session promises to provide deep insights into the company’s strategic direction and ongoing projects, particularly focusing on their clinical pipeline that addresses significant medical needs.

Baird Global Healthcare Conference

Additionally, Oculis will be present at the Baird Global Healthcare Conference on September 9-10, also held in New York. Dr. Sherif will deliver a company update on September 9 at 3:45 PM ET, sharing developments and advancements within Oculis's innovative pipeline. Attendees will have the chance to ask questions, facilitating a more interactive engagement with the management team.

Pareto Securities 16th Annual Healthcare Conference

The following week, on September 16, Oculis will participate in the Pareto Securities 16th Annual Healthcare Conference in Stockholm. Páll Ragnar Jóhannesson, Chief Business Officer, is scheduled to present a company update at 9:15 AM CET. This will be an exceptional opportunity to connect with investors from various regions and discuss the latest advancements in their product candidates.

Leerink Partners Biopharma Summit

Later in the month, September 17-19 will see Oculis at the Leerink Partners Biopharma Summit in Healdsburg. Dr. Sherif will again represent the company, affirming his commitment to investor relations and transparency in business operations.

Opportunities for One-on-One Meetings

Throughout these conferences, Oculis will be available for one-on-one meetings, allowing personalized interactions between the management team and interested investors. Those who wish to schedule a meeting are encouraged to reach out through their representatives at the sponsoring institutions.

Oculis’s Commitment to Innovation

Oculis is dedicated to addressing the unmet medical needs in ophthalmic and neuro-ophthalmic conditions. Their late-stage clinical pipeline is immensely promising, featuring three core product candidates: OCS-01, OCS-05, and OCS-02. OCS-01 is currently undergoing pivotal registration studies aimed at becoming the first non-invasive topical treatment for diabetic macular edema.

On the other hand, Privosegtor (OCS-05), currently in Phase 2 trials, is targeting acute optic neuritis, underscoring the company's commitment to treatments with broad clinical applications. Lastly, Licaminlimab (OCS-02) is being developed for dry eye disease, utilizing a personalized medicine approach.

Headquartered in Switzerland and with operations extending into the U.S. and Iceland, Oculis boasts a robust management team supported by prominent international healthcare investors, ready to tackle the challenges in the biopharmaceutical industry.

Frequently Asked Questions

What is Oculis focusing on in the upcoming investor conferences?

Oculis will discuss their innovative solutions for ophthalmic and neuro-ophthalmic diseases, engaging directly with investors.

Who from Oculis will be attending the conferences?

Riad Sherif, M.D., CEO, and Sylvia Cheung, CFO, are among the key participants scheduled to attend.

Why are these conferences significant for Oculis?

These conferences provide Oculis an opportunity to showcase their advancements, connect with investors, and explore future collaborations.

What are the key product candidates Oculis is developing?

Oculis is developing OCS-01, OCS-05, and OCS-02, focusing on unmet needs in ophthalmic treatments.

How can investors participate in one-on-one meetings?

Interested investors can schedule meetings by contacting representatives at the sponsoring institutions during the conferences.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.